Amgen Hands Omecamtiv Back To Cytokinetics

Cytokinetics Assessing Commercializing On Its Own Or With New Partner

 
• By Mandy Jackson
  
Two female hands holding a 3d printed human heart
Amgen handed omecamtiv mecarbil back to Cytokinetics after data didn't meet a "high bar" in a Phase III heart failure trial • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business